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Abstract
Background: Dementia is becoming one of the most important emerging public health concerns in a generation.
In societal approaches to the mitigation of major disease ‘burden’, population screening can sometimes provide an
effective approach to improving detection of disease and outcomes. However the acceptability of a systematic
population screening programme for dementia, to the British public, is not known.
Methods: A Patient and Public Involvement (PPI) event was organised to give members of the public from the
East of England an opportunity to offer their perspectives and to comment on the findings of a systematic
literature review looking at attitudes and preferences towards screening for dementia. The event was attended
by 36 members of the public and eight national Alzheimer’s Society Research Network volunteers. The morning
discussion contained a presentation, which defined population screening for attendees but contained no reference
to the findings of the review. In the afternoon, findings of the review were presented and a discussion on the
results was facilitated. The discussions were recorded, transcribed and subjected to thematic analysis. The NVivo
qualitative data software was used to facilitate this process.
Results: A total of 23 key themes emerged in relation to the carer and general population. The most frequent
themes which emerged were the low levels of understanding and awareness around the dementia syndrome;
the acceptability and validity of any tests; costs to the National Health Service (NHS); an individual’s existing health
status existing health status; financial/profit motive for screening; the inability to change prognosis; and the
importance and availability of support.
Conclusions: Factors such as personal beliefs, experiences and attitudes to health impact on decisions to be screened
for dementia. A number of additional concerns were raised which were not previously identified in the systematic
literature review. These were around the economic incentives for screening (profit motive), the provision of social
support, and the economic/social impacts of screening programmes. This may reflect cultural differences in health
and social care funding models between Britain and other countries where previous research was conducted.
Background
Despite the best efforts of clinicians and researchers to im-
prove the detection of dementia, many people still do not
receive a formal diagnosis or receive it late in the disease
progression [1]. To address this issue the EU joint action
programme ALCOVE (Alzheimer’s Cooperative Valuation
in Europe) is conducting research seeking to compare
national recommendations for diagnosis and develop rec-
ommendations to “improve early diagnosis”. Screening has
been proposed as one mechanism to improve both rates of
diagnosis and patient care outcomes. In the UK doctors are
recommended to “proactively” ask patients at risk of de-
mentia about their memory, and offer a screening test [2];
however guidance produced by the UK National Screening
Committee [3], the Royal Australian College of General
Practitioners [4], and the US Preventative Services Task
Force [5] advises against the adoption of screening for the
early detection of dementia given the number of difficulties
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in implementing a screening programme [1, 4, 6], the lack
of evidence that dementia fulfils established criteria to jus-
tify screening [3–5] or that such a screening programme
would be acceptable to the clinicians, patients, carers or the
public [7].
Our group has conducted a systematic review of re-
search to date [7] on the attitudes and preferences of
healthcare professionals, people with dementia, caregivers
and members of the general public to dementia screening.
The findings of the review suggest that screening for de-
mentia raises complex issues around preference and
choice for clinicians and the public: while some would
favour a screening intervention, such an approach may
not be amenable to all. However, the published literature
on attitudes towards population screening for dementia is
diverse and fragmented and it is unclear what specific fac-
tors promote or reduce screening acceptance the most
therefore it is difficult to draw clear conclusions. Given
the paucity of evidence on public opinion the acceptability
of dementia screening is still unclear. A PPI (Patient and
Public Involvement) event was organised to facilitate
members of the public in the East of England to talk about
their views on population screening for dementia. The
aim was to contextualise the findings of a systematic
review [7] for a British audience.
Approach
The integration of PPI into public health research is
becoming increasingly important in the UK. There is
growing recognition that lay individuals need to be in-
volved in the scientific process [8, 9. It is believed that
the involvement of lay members of the public may lead
to the generation of new research questions or hypoth-
eses, enhance the relevance and applicability of findings,
and lead to the reprioritisation of research and policy.
Methods
A PPI event was organised on the 5th June 2013. Delegates
attending the event were viewed as partners rather than
research subjects in order to generate data and evidence
collectively. In this exercise, The National Coordinating
Centre for Public Engagement definition was used; “Public
engagement describes the myriad of ways in which the
activity and benefits of higher education and research can
be shared with the public. Engagement is by definition a
two-way process, involving interaction and listening, with
the goal of generating mutual benefit” [10]. This PPI evalu-
ation is based on the reporting standards set forward in the
GRIPP (Guidance for Reporting Involvement of Patients
and Public) checklist [11].
Description of involvement activity
Members of the public were invited to attend a one day
event held in Cambridge City (UK) by a firm experienced
in recruiting (detail presented below). The event was
jointly organised by the Alzheimer’s Society (East and
London Regions) and the University of Cambridge. The
PPI event was a consultation during the final stages of the
systematic reviewing process. The morning discussion was
framed around a general presentation conducted by a
member of the research team (LL) and undertaken to
define screening. It contained no reference to the findings
of the systematic review. In the afternoon the aims of the
review, methodology, analysis strategy, and findings were
presented. The focus of this PPI event was on the screen-
ing of asymptomatic individuals using paper and pencil
tests. A discussion (in groups of no more than 12 people)
on the meaning of those findings for attendees was facili-
tated. Attendees were divided into broadly age-banded
groups with the ASRN (Alzheimer’s Society Research
Network) members in a separate group from the wider
public groups. The ASRN is constituted of volunteers,
usually people with dementia or their carers.
Recruitment of partners
General public: The research team considered what the
target audience’s specific needs may be, in terms of both
the best approach to recruitment and the best approach to
getting people engaged in a project and approached a pri-
vate firm to undertake recruitment. A purposive approach
was adopted to ensure engagement with a cross-section of
the public in the locations selected. The University of
Cambridge provided a sample specification together with
a screening letter and consent form. We would try to re-
cruit a representative sample based on the 2011 census for
Cambridge, England (16.4 % aged 65 and over; 50 % for
both male and female; 60 % in an occupation). Adherence
to these demographics was not strict. The recruiters then
used a range of methods for free-finding participants
including on-street recruitment, approaching areas where
the target audience is more likely to visit, for example if
the target was older people they could work with local
services providing facilities for older people. Strict proto-
cols were in place for managing personal data. All partners
signed a consent form before the event, at the point of
recruitment the recruiter asked the respondent to read
and sign the form. Forms were then returned to the
University of Cambridge via special delivery. Any partners
that were missed were then contacted and consent pro-
vided via email. Respondents were also asked about spe-
cial dietary requirements and mobility issues.
Alzheimer’s Society group: The ASRN recruited mem-
bers of this group. An initial e-mail was sent to Eastern re-
gion members to ascertain initial interest. Those interested
in participating indicated by email and were subsequently
provided with the dates, times and venue of the event. A
consent form was signed before the event and returned to
the University of Cambridge.
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Description of partners
A total of 50 people were invited to participate in the PPI
event (Table 1). The event was well attended, with 36
members of the general public from across Cambridge-
shire and eight ASRN volunteers. No one attending the
event identified themselves as having dementia, however,
eight people in attendance had a member of their family
with dementia, ten had cared for someone with dementia
and five worked with people with dementia, eleven re-
ported they had little or no direct experience of dementia.
The PPI event involved two ASRN monitors in the man-
agement committee; both had a role in the development
and preparation leading to the event but did not partici-
pate in the group discussions.
Detail of discussion
A quasi-focus group format was used to collect the per-
spectives from those present. There was no interview
schedule for the discussion groups; the round table
debates were based on the issues raised by our partners
and the review. The comments of those attending the
event were recorded by a facilitator on a flip chart (and
electronically) and subsequently reported back once all
participants had reconvened. The discussions were then
transcribed and subjected to thematic analysis using the
NVivo qualitative data software package. Members of the
research team (LL and SM) made themselves available to
speak with attendees after the event to answer any
remaining questions, or to provide clarification or advice.
Questionnaires
Questionnaires were handed to partners attending the
event at the beginning and end of the day. These ques-
tionnaires collected data on attitudes and preferences to
screening for dementia, and were undertaken to examine
the degree to which attitudes and preferences changed
during the event (Table 2).
Economic appraisal
In recognition of participants’ time and to mitigate the
risk of participant dropout, a fixed monetary honorarium
of £80 was offered and reminder calls were made in
advance of the event. Costs for supportive care were pro-
vided to partners if they attended without their care recip-
ients, and travel costs. The organisational costs (including
food and venue) reached a total of £1206. Recruitment
and payment of partners and administrative support for
the event cost a total of £4,075. Stationary and printing
cost a total of £40, while money for ASRN participants
was a total of £480. Other costs included £255 for tran-
scription of recordings. In total the cost of the public
event was £6,056.
Analysis
Thematic analysis was undertaken independently by two
researchers (SM and LL). Two reviewers worked inde-
pendently and then compared findings to produce a
mutually agreed coding framework; also informed by a
previous systematic review [8]. Statements related to the
partner’s perceptions, views and/or attitudes and/or expe-
riences, ethical, moral and cultural opinions were coded
and analysed in NVivo. Data were synthesised and themes
were agreed. Rater discrepancies were resolved through
discussion. We then analysed the nature of the evidence
on attitudes and preferences of three key time periods of
screening: (1) pre-screening, (2) in-screening and (3) post-
screening periods. Summaries were sent to PPI partners
to read and critique. By involving our PPI partners in the
analysis we were able to have members of the general pub-
lic inform our interpretation and synthesis of the data.
While the authors retained editorial control over the ana-
lysis, considerable weight was given to their comments.
Partners’ responses to the summaries were confirmatory
of the authors’ data interpretation. Descriptive analysis
was undertaken on the questionnaire data.
Results
Context
Findings from a systematic review of attitudes and pref-
erences towards screening for dementia [7] were largely
drawn from studies undertaken in non-UK healthcare
contexts. Both the research team and the funders, a
major UK dementia charity, felt it important that the re-
view be contextualised to better understand the finding’s
relevance to the UK and enhance the review’s impact.
Themes
From the discussions at the event 23 key themes emerged.
A framework was developed that divided the screening
process into 3 stages: (1) pre-screening, (2) in-screening
and (3) post-screening periods (Fig. 1). Pre-screen: existing
care, existing health status and other screening experience.
Table 1 Participants at PPI event
Female n = 25 (50 %)
Male n = 19 (38 %)
Withheld information n = 6 (12 %)
Aged under 35 n = 11 (22 %)
Aged 35–44 n = 6 (12 %)
Aged 45–54 n = 6 (12 %)
Aged 55–64 n = 11 (22 %)
Aged 65–74 n = 7 (14 %)
Aged over 75 n = 5 (10 %)
Withheld information n = 4 (8 %)
Martin et al. BMC Geriatrics _#####################_ Page 3 of 13
Table 2 Pre/post screening questionnaire results
Question Before After
I think I have more problems with my memory
than others my age
72 % no 75 % no
13 % yes 15 % yes
(6 missing item response) (4 missing item response)
Has a doctor told you that you have a problem
with your memory
88 % no 88 % no
12 % yes 12 % yes
(4 missing item response) (4 missing item response)
I would like to know if I have a problem with
my memory
13 % strongly agreed 13 % strongly agreed
34 % agreed 36 % agreed
25 % unsure 18 % unsure
11 % disagreed 18 % disagreed
6 % strongly disagreed 24 % strongly disagreed
(4 missing item response) (4 missing item response)
I would like to know if I am more likely than
others to have dementia
11 % strongly agreed 13 % strongly agreed
34 % agreed 36 % agreed
27 % unsure 18 % unsure
15 % disagreed 18 % disagreed
12 % strongly disagreed 24 % strongly disagreed
(4 missing item response) (4 missing item response)
I would like to know I have dementia 13 % strongly agreed 11 % strongly agreed
40 % agreed 34 % agreed
20 % unsure 13 % unsure
11 % disagreed 25 % disagreed
24 % strongly disagreed 24 % strongly disagreed
(4 missing item response) (4 missing item response)
How often would you like to be tested after 5 people said yearly
4 people said every 2 years
3 people said every 5 years
1 person said once a decade
4 people said they didn’t know
6 people said never
11 people made no response
1 person said from age 45 - every 2 years
1 person said until scientifically proven
1 person said depends on test
1 person said if symptoms present
3 people said as required
1 person said Memory
test. Biomarkers
People should be tested for dementia 18 % strongly agree 20 % strongly agree
50 % agree 20 % agree
15 % unsure 18 % unsure
1 disagree 15 % disagree
2 strongly disagree 11 % strongly disagree
(4 people withheld information) (4 people withheld information)
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Table 2 Pre/post screening questionnaire results (Continued)
People should be tested for colon cancer 25 % strongly agree 29 % strongly agree
56 % agree 43 % agree
3 unsure 9 % unsure
No one disagreed 6 % disagree
1 strongly disagree No one strongly disagreed
(4 people withheld information) (4 people withheld information)
People should be tested for depression 18 % strongly agree 25 % strongly agree
47 % agree 25 % agree
20 % unsure 22 % unsure
1 disagree 15 % disagree
No one strongly disagreed No one strongly disagreed
(4 people withheld information) (4 people withheld information)
Being tested for dementia can cause no harm 15 % strongly agree 18 % strongly agree
25 % agree 9 % agree
38 % unsure 29 % unsure
1 disagree 20 % disagree
9 % strongly disagree 11 % strongly disagree
(4 people withheld information) (4 people withheld information)
I didn’t find these questions difficult
(NB: People found this question ambiguous)
38 % strongly agree 29 % strongly agree
45 % agree 43 % agree
1 unsure 2 unsure
1 disagree 3 disagree
1 strongly disagree 1 strongly disagree
(4 people withheld information) (6 people withheld information)
Fig. 1 Model of themes identified
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In-screen: the screening tool, role of clinician, how to
test, learning the test, who to conduct the screen, rela-
tionship to doctor and awareness of the disease. Post-
screen: social impact, the screen result, prognosis and
stigma. Many of the themes were influenced by the in-
dividual’s social context such as; lifestyle and life view,
role of family, role of support. Also the wider health
and social care organisational context such as financial
motives, costs, on whom to target the screening test,
organisational pressures, and planning.
Themes only raised by the ASRN group included the re-
lationship to the doctor, organisational pressures and the
social impact of dementia screening. Themes exclusive to
the general public group were training for staff, and the
role of the family (Table 3). A summary of themes can be
found in Table 4; a comprehensive table is provided as
Additional file 1: Table S1.
Pre-screen
1. Existing care
Delegates with existing care needs mentioned that their
current health was an important factor when deciding if
they would attend for a screening test: “I mean if you
are in the system […] or you’re in the hospital, you see a
sign and think ‘Oh yes […] perhaps I should be doing
that!” Conversely, experience of poor quality care makes
individuals less likely to attend screening. Attendees who
had witnessed poor care also indicated that this was an
additional factor that would make them less likely to
attend.
2. Existing health status
There was no consensus on the impact of an individual’s
existing health status towards a decision to screen. While
most thought that an awareness of conditions would re-
sult in improved care “You’ve already been diagnosed with
something and they’re helping […] which would create
more confidence”. Others argued that knowing would
make individuals “worry more”. There was a high level of
variation between responses.
3. Other screening experience
Experiences of other screening tests and programmes
were discussed, most commonly breast and cervical can-
cer screening. Screening for dementia however; “that’s
completely different, the way you think about it and antici-
pate it”. Previous screening experience was seen as rele-
vant but how far such experience or lack of experience
might affect individual decision-making was unclear.
In-screen
1. The screening tool
Attendees had a number of concerns regarding test accur-
acy. Many wanted to have evidence that the test works ef-
fectively before undertaking a screen; “I’d want to know
how effective it is […] I’d want to be given some figures”;
“Yeah, the accuracy of the test is everything”. Concerns
were also raised around pen and paper tests, which may
not be understood by everyone, given language and cul-
tural differences. Where partners had experience of being
tested for dementia they noted the Mini-Mental State
Examination as being a particularly “stressful” tool.
2. Role of the clinician
Some delegates argued that there is insufficient agree-
ment on screening within the health profession to make
it a viable programme “(My) daughter (is) qualified (as a
doctor) and she was treating people […] and saying has
their dementia been managed […] and consultants were
saying to her well, they’re not diagnosed with dementia
[…] She’s always trying to get them care plans and fight-
ing for their support, but […] I think there’s a lot of work
to be done, and not just in the community”.
3. How to test
There was no consensus on how a screen should be
undertaken. The idea of computerised or web-based
screening was popular, as was brain imaging and genetic
testing; “Would brain scans be appropriate for a screen-
ing?”; “The form of screening that I would opt for [..] would
be to go and have the head scan”. Delegates were
reminded that pen and paper tests were the focus of the
Table 3 Overlapping themes at PPI event
Themes exclusive to Alzheimer’s group Themes exclusive to general public
Relationship to doctor Organisational pressures Provision of information Role of culture
Social impact Training for staff
Themes which crossed boundaries
Who to target Role of support Stigma Who should conduct the screen
Suitability of the test Costs Lack of ability to change prognosis Financial motive
Role of planning Existing health Acceptability of test Level of screen inaccuracy
Awareness of disease Existing care Role of family
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Table 4 Themes identified in studies
Pre-screen
Theme Evidence
Accuracy of the test “I’d want to know how effective it is… I’d want to be given some figures”; “Yeah, the accuracy of the test is
everything. At the moment it’s our considered opinion that the test is in its infancy”.
“But what are you going to screen for? In bowel screening and in breast screening it’s quite clearly known what
you’re searching for and it’s quite clearly known what you’re going to do if you find it. My first question is what
are you going to screen for?”
Existing care “A lot of the staff members… treated them (patients) like animals”.
“I mean if you are in the system already you’re much more likely to see the publicity about do you want to
join… you know, sign up in the thing, you know, you’re more… or you’re in the hospital you see a sign and
think oh yes… perhaps I should be doing that!”
Existing health state “You’ve already been diagnosed with something and they’re helping, and you’re being treated, so there is a
cause and an answer which would create more confidence”.
“Worry more”.
Experience with disease There was no consensus between those with experience of the disease and those without. Some, with
experience, argued, “I have a few acquaintances who have dementia, and it makes it much more real”. These
were more likely to accept screening. However, some had family members with the disease and were dissuaded
from undertaking the screen because of this experience: “Having someone in the family or close with a condition
does not make you any more likely to seek answers for it”.
Some argued that previous experience had no bearing on what is perceived as an individual choice: “Having
someone in the family, I wouldn’t say affects you at all, affects your likelihood of going for screening at all”.
Financial motive “Somebody could make money”;
“I would have suspicions if it was being done by a drug company”.
Lifestyle and life view “It’s the balance… of what you have to go through for the screening… what the benefits are, you get a return,
or carers get a return, it’s that sort of balance”.
“Yeah, exactly, it’s a personal choice, and I think if you know that your lifestyle could lead to dementia you’d
probably be more comfortable with your lifestyle and not want to worry about dementia.”
Other screening experience “Is very invasive of your body”.
“That’s completely different, the way you think about it and anticipate it”.
Role of clinician “My daughter (is) qualified (as doctor), she was treating people… going to discharge them and saying has their
dementia been managed… and consultants were saying to her ‘Well, they’re not diagnosed with dementia’…
She’s always trying to get them care plans and fighting for their support, but you know, while it’s not even
known widely at that level amongst the professionals, then I think there’s a lot of work to be done, and not just
in the community”.
Role of culture “My wife is Chilean, and when we go over there it is a family concern over there, they really do look after each
other”.
“I live in the Philippines most of the year and I have a big extended family, and they look after me… and it is
one advantage you have in third world countries, they have extended families… there is no suffering”.
Role of family “A lot of people tend to keep it in the family, than let outsiders know that it is happening, don’t they? That is the
problem.”
“It sounds dreadful but in fact, it is true isn’t it, for a family to have to learn that some member of the family is
going to come down… be felled by this disease is just awful. You’re living on a knife edge and borrowed time”.
Who to target? “School”.
“You should target everyone rather than a certain group of people like based on age or ethnicity or experience
or whatever”.
In-screen
Theme Evidence
How to test “Would brain scans be appropriate for a screening”.
“The form of screening that I would opt for, if there was a choice, would be to go and have the head scan
because it shows whether you’ve got Parkinson’s or Alzheimer’s. I mean, I do know that because that’s how we
found out my mother had got it, and my uncle, and what they’d got, because green, I think it’s green, or was it
blue, is the Alzheimer’s, red is the Parkinson’s”.
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Table 4 Themes identified in studies (Continued)
Learning of test “Yeah, the woman actually went in there and she did a test, a memory test with my mother, and my mother
already previously knew that this woman was coming because they have to tell them, and I went, and I was
sitting there and I’m thinking… well, you’re asking her questions that she’s already logged in her head and she
knows, and she’s going to reel them off, as she was doing”.
Organisational pressures “The doctor doesn’t have time, you know, you rush in, you’ve got five minutes, and away you go, so if you have
two ailments and you have two questions you have to get another appointment, so you know, why is this
doctor doing the screening?”
“It would put more pressure on the GPs because they would have to have training, which means more closed
surgery days, and they will have to have special times to do that, you can’t do it on a normal ten minute
appointment. So yeah, that would put pressure on them to be honest”.
Relationship to doctor and
health
“I think if you’ve got a good rapport with your doctor, you feel comfortable, and probably with a doctor you’re
familiar with, they spend a bit more time with you than a doctor you don’t know, so I think that probably… well,
in my case it would make it easier”.
“Even if you just visit regularly for different things, and if you have the same GP you see all the time, if they
come and suggest this screening… you might be more inclined to accept it. Because otherwise, if you see a
different GP every time and one of them offers it to you, you say no, I’ll pass. I think that, yeah”.
Training needs for staff “Well they need to be trained, it’s got to be someone who’s trained… and it’s not going to be achieved”.
“It’s got to be somebody trained to do that and not anything else”.
“Yes, we’re looking for the good test that a trained person can administer”.
Who should conduct the screen? “I think as a general practitioner they get five minutes with you, and to make decisions you know… so maybe
you’re better off with a more specialist… somebody who deals with this”.
“A carer that does a test”.
“Family, carers, nurses”.
Post-screen
Theme Evidence
Planning “Rather know to be prepared, you know, set things in place before you are in a state where you can’t remember
anything”.
“Don’t know whether I’m going to end up in a wheelchair or not”.
Role of support “Getting them involved in providing a good support network for each other, to be there for each other as well
as the person affected, and I think it probably just wakens people up to just sort of try and have a better quality
of life rather than dwell on problems and depression and bad weather”.
“Screening cannot interfere with my life. As a woman I have many different roles in my home, looking at my
family and husband and depending on what is happening, I might not have time to go for screening”.
Social impact “One of the things that would put me off I think is like… maybe you test positive… what if that (information)
gets into the wrong hands, like employers or like… that can affect you too, like ‘Oh well we won’t employ that
group because…’ Someone’s got information somewhere about you which is possibly… that’s what would put
me off, that would be a negative”.
“But if you’re going to risk losing your job, if you’re going to risk losing whatever in your current lifestyle, then
you’ll probably back off until there is a precise treatment”.
The screen result “I am not sure knowing actually benefits me”.
“If you’re the kind of person who hides from the truth and reality, you’re not going to be any more likely to go”.
“I’d definitely want to know. I’ve seen it with my father, and my mother trying to hide it from everybody, she was
frightened to death of what people would say, and even neighbours she tried to hide it from them, and you
know it was ridiculous really, but she just wouldn’t get advice or help: ‘I can cope, I can cope’”.
Themes which cut across the pre-, in-, and post-screen process
Acceptance of test
“I wouldn’t want to be screened… if there was any side effects or if the test got too intrusive”.
“If you said a simple written test, it’s not a simple written test for anyone who can’t write… so a simple written test will eliminate quite a fair number
of people”.
Awareness of disease
“Alzheimer’s is one of these nebulous, I am not really sure what it is”.
“Alzheimer’s… there is somewhere around 100 different forms of Alzheimer’s”.
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review [7], but conversations repeatedly returned to brain
scans and genetic testing, so there is insufficient evidence
to draw any robust conclusions on the attitudes and pref-
erences towards simpler screening tests.
4. Learning the test (repeated test exposure)
For those delegates who did discuss the use of pen and
paper based screening tests, there were some concerns
that the test itself may become less effective over time
“Yeah, the woman actually went in there and she did a
test […] and I’m thinking […] ‘Well, you’re asking her ques-
tions that she’s already logged in her head and she knows,
and she’s going to reel them off ’, as she was doing”.
5. Who should conduct the screening test?
There was no strong preference for a particular health-
care professional to administer the screen; however dele-
gates agreed that it should be a trained individual. The
most frequently cited examples were the patient’s owns
doctor, nurse, or a memory specialist: “I would prefer a
doctor, my own GP”; “It could be a memory clinic […] it
could be a department of the hospital”; “Well, have
mobile vans coming round!”; “Social Services”; “Family,
carers, nurses”.
6. Relationship to doctor & health care system
The relationship to the doctor was seen as central to the
decision to screen “I think if you’ve got a good rapport with
your doctor […] it would make it easier”; “Even if you just
visit regularly for different things, […] you might be more
inclined to accept it”. For some attendees the relationship
was correlated with the existence of comorbidities; “I
mean if you have two illnesses you’re much more likely to
have a rapport with your clinician aren’t you?”.
7. Awareness of the disease
Awareness of dementia could both increase and decrease
the likelihood of attending dementia screening. Some del-
egates with experience of caring argued that those with
“acquaintances who have dementia” were more likely to
accept screening because it “makes it much more real”;
however, some carers were unenthusiastic: “having some-
one in the family or close with a condition does not make
you any more likely to seek answers for it”. Some argued
that previous experience had no bearing on what is per-
ceived as an individual choice: “having someone in the
family I wouldn’t say […] affects your likelihood of going
for screening at all”.
There was some uncertainty over the syndrome, how
it would impact on their life and on their family,
friends and social contacts “Alzheimer's is one of these
nebulous […] I am not really sure what it is”; “how far
(has) science or knowledge has gone with regards to
understanding Alzheimer’s or dementia. Are they two
words for the same thing?” There were also some
uncertainty over the cause of illness: “Maybe it could
be down to stress […] I don’t know […] fertilizer they
Table 4 Themes identified in studies (Continued)
Costs “If there is no positive implications (no cure), is it worth spending the money”;
“That’s an awful lot of money in terms of paying the doctors and time taken off their work”;
“It would probably be very expensive”; “It could be better spent”; “Well it’s a waste of money”;
“There is no funding for this”; “I mean unless they’re going to put money into the system it’s actually
fairly pointless”.
“There’s more and more money being taken out of the NHS, and this system, screening,
is requiring more money not fewer doctors and nurses and care workers. So why…
forget it, put the money into research. Forget the screening”.
Lack of ability to change
prognosis
“I’d still rather be in my house where I’ve got a familiar environment to me, and I know where… especially if I
know my brain is deteriorating, the last thing I’d want is to be surrounded by strangers in a completely different
environment and everything’s in a set regime and all that sort of stuff. So I think yeah, a care home is probably
the last place I’d want to be”.
“I’d probably change my opinion on it if I knew for certain there was actually a treatment for it that worked.
But at the moment I just think there’s so much research, but there’s no treatment for it”;
“I think you’re better not knowing nothing about it at all, personally speaking I’d rather not know at all, but I…
I could be influenced”.
Patient Benefit “Dementia, it’s one of those ones where if you get it there’s not much you can do about it,
so unless I had specific reasons to do it I don’t think I’d have it”
“(They) see it as quite positive really, I think I am lucky to live in a country where there is this sort of
screen for this disease”.
Stigma “I think there’s a sort of stigma attached to going for screening, and people will be ducking and diving,
you know, so I think it’s important”; “If you are not careful you are going to be labelled”;
“Because of the stigma”; “Rightly or wrongly, it has a stigma”.
“People (would be) judging you for an illness (and this) shouldn’t really be right”;
“Too many of the population have a stigma, you know, and… just because they don’t know how to
handle it in my view”.
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put on food”; “Some say it’s the scrapings off the pot,
when you’re cooking using a grey aluminium pot”.
Post-screen
1. Social impact
There were a number of concerns about the societal im-
pact of screening “I think all that might do is just engender
tremendous anxiety in the population at large”; “I think we
think it could be detrimental and it also […] it’s unneces-
sary”. There were confidentiality concerns that the screen
result would be disseminated wider than healthcare
professionals: “One of the things that would put me off I
think is […] What if that (information) gets into the wrong
hands, like employers […] that would be a negative”.
2. The screen result
There was wide-ranging discussion of potential reactions
to receiving the screening result. Whilst some delegates
would want to know their results “You should find out
for the sake of it”; “(if I knew) I wouldn’t have the stress
of worrying about it”, others preferred not to know. For
some it was like being “given a death sentence”; “It’s you
slowly drown into pretty much a vegetable”. Another
responded “I mean, excuse my bluntness, but if someone
finds out […] that you will be completely forgetful and a
drooling mess […] and we don’t want to be that”. Some
comments were more neutral “from what we know right
now … I am not sure knowing actually benefits me”. One
delegate said “If I discover I have dementia then Jesus!
My whole life and perception will change and try and
shape things the other way around.”
3. Lack of effective treatment and prognosis
The unavailability of a cure was a concern for a large
number of delegates and appears to have an impact on
screening decisions. One noted: “You’re still facing the
possibility of being told that you might have a disease for
which there is no cure”; “dementia, it’s one of those ones
where if you get it there’s not much you can do about it”.
For some they would only attend a screen if the disease
could be cured: “If there was a cure or they could head
off that disease that would be something to encourage
you for it, for a test”. While the lack of an available cure
is a significant concern, there were also fears that exist-
ing treatments are inadequate. Importantly, some people
expressed the view that their attitudes may be subject to
change: “I’d probably change my opinion on it if I knew for
certain there was actually a treatment for it that worked.”
Few people in the ASRN group saw a benefit to screen-
ing in the current context. The overall mood was charac-
terised by a form of fatalism “You can’t change what’s
going to happen and what’s not going to happen”. One
delegate felt these views were not necessarily an argument
against offering screening: “it is my choice, so I would be
informed about it beforehand and then I would make my
choice, so I don't see a problem there”.
4. Stigma
For some attendees the perceived stigma of undertaking a
screen test had a negative impact on their willingness to
be screened: “I think there’s a sort of stigma attached to go-
ing for screening”; “If you are not careful you are going to
be labelled”; “…because of the stigma”; “Rightly or wrongly
it has a stigma”. There was a belief that “people (would be)
judging you for an illness (and this) shouldn’t really be
right”; “Too many of the population have a stigma […] just
because they don’t know how to handle it”. One delegate
got particularly emotional on this issue “I’ve been a carer,
and you have 10 min with that patient, they’re a human
being for God’s sake”; however, it was also argued that the
level of stigma encountered by those with dementia is
reducing across the society: “mental health and everything
[…] now it’s not so much stigmatised, you know”.
Cross-cutting themes
1. Lifestyle and life view
Lifestyle and life view were also important determinants,
both the perception that certain lifestyles might affect
dementia risk and the anticipation of lifestyle changes:
“If you’re going to risk losing your job […] losing whatever
[…] then you’ll probably back off until there is a precise
treatment”; “I think if you know that your lifestyle could
lead to dementia you’d probably […] not want to worry
about dementia”. Personal circumstances, such as having
children or other dependents could affect decision-
making. Mostly those with young children felt a respon-
sibility to be screened, but others said it was more
important for them to “get on with family life”.
2. Role of family
The family plays a complex role in determining an indi-
vidual’s decision to attend a screen for dementia. Families
may disregard someone’s own concerns; one delegate
mentioned a friend whose “husband refused to take her”
to the doctors. Adding that the experience “was upsetting
and worrying for her […] it was terribly distressing”. Fam-
ilies may also keep a dementia diagnosis to themselves “A
lot of people tend to keep it in the family, [rather] than let
outsiders know that it is happening, don't they”. Some del-
egates spoke about a shared experience “It sounds dread-
ful, but in fact it is true, isn’t it, for a family […] You’re
living on a knife edge and borrowed time”. Issues around
having a family and being female were also raised “screen-
ing cannot interfere with my life, as a woman I have many
different roles in my home, looking at my family and hus-
band and depending on what is happening, I might not
have time to go for screening”.
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Delegates from black and minority ethnic communities
spoke about their cultural differences, in particular the
role of the extended family which was seen as beneficial
“it is not a problem, because you have people around”;
“one advantage you have in third world countries, they
have extended families […]. There is no suffering”. They
spoke about the divisions of labour, the delegation of
jobs and caring responsibilities within the family and
home environment “when we go over there it is a family
concern over there, they really do look after each other”.
3. Role of support
Availability of support was one of the main themes emer-
ging from all groups; “You can’t cure it, but if there’d have
been some help”; “I would want to live my life and not to
worry, but if I was diagnosed with dementia and I had the
right support around me, fair enough, I’d like to do things”;
“getting them involved in providing a good support network
for each other, to be there for each other as well as the per-
son affected”. It was also recognised that the provision of
support was not related to the provision of screening “you
can get all of that without screening”.
4. Financial motive
A financial motive for screening was discussed in seven of
the eight groups. There was a large degree of scepticism
about the reasons screening was being discussed: “some-
body could make money”. A number of attendees believed
that the adoption of dementia screening was to improve
their GPs’ “pay scale”. Pharmaceutical companies in par-
ticular were believed to be behind the drive for screening
aiming for a further “push on drugs”. Many delegates men-
tioned that they “would have suspicions if it (the screening)
was being done by a drug company”. Some delegates ar-
gued that “the media [are] selling it (dementia) as a fear
tactic”. There was also a fear that insurance companies
would also abuse the screen results, mentioning concerns
that, if screened, people “risked” being “clobbered for higher
insurance”. There was general agreed scepticism over the
profit motive in provision of other care services, that
seemed to colour views on postulated economic drivers for
screening, “now it is done on a commercial basis, on com-
mercial terms, which are getting a profit out of it”.
5. Who to target
There was no agreement on who should be invited for de-
mentia screening, and little awareness of the factors that
might determine why a screening programme might target
certain groups. No discussion groups raised relevant ques-
tions such as "When does dementia become more com-
mon?" or "Is there any evidence that can show how well
these tests identify dementia at different ages?" One per-
son noted that “You should target everyone rather than a
certain group of people”. The youngest group which was
recommended as a target was “school age” children, others
suggested “40 and upwards”. While older age is a risk
factor for dementia very few delegates identified this
population as the target for any screening intervention.
The exceptions were some of the ASRN delegates who
were happy with the age specifications set in quality
standards such as the Commissioning for Quality and
Innovation targets set by the UK Department of Health [1].
6. Organisational pressures
There were a number of concerns from delegates re-
garding the logistics of offering screening through gen-
eral practice, mostly from an organisational and training
perspective: “The doctor doesn’t have time. You know,
you rush in, you’ve got 5 min, and away you go”. Another
delegate noted “It would put more pressure on the GPs
because they would have to have training […] you can’t
do it on a normal 10 min appointment”.
7. Training needs
There was a concern that with any new programme
there are new skill requirements “which means more
closed surgery days”. The groups did reach a consensus
and indicated that the individuals administering the
screen needed the adequate training to do so; no one
was willing to be screened by untrained individuals.
There was a significant concern that unqualified and un-
trained individuals may make unacceptable errors result-
ing in additional concern for the patients “It’s got to be
somebody trained to do that and not anything else”.
8. Planning
The need for planning after the test was raised in a number
of groups. Some would “set things in place before you are in
a state where you can’t remember anything.” For these par-
ticipants the opportunity to make legal arrangements, such
as a lasting power of attorney, was very important; this
was raised in 3 of the 8 groups. Time to make other
preparations, not necessarily dementia-specific, came up
too; one delegate said that they had already started chan-
ging furniture and preparing their home for old age “I
don’t know whether I’m going to end up in a wheelchair or
not”. Conversely, some would not attempt to plan for the
future; “for me [it’s] not to do with jobs or insurance…just
lifestyle “. And some would not want to try to change their
lifestyle, “You can't be cured anyway, my guess is. Yes, have
another glass and forget it all”.
9. Costs
For most delegates cost was a major factor; “If there is no
positive implications, is it worth spending the money?”;
“That’s an awful lot of money in terms of paying the doctors
and time taken off their work”; “It could be better spent”;
“Well, it’s a waste of money”; “There is no funding for this”.
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“There’s more and more money being taken out of the NHS
[…] forget it, put the money into research. Forget the screen-
ing”. Delegates from the ASRN had very strong preferences
not to spend money on screening but on "research".
Questionnaire results
Responses to the pre-post questionnaire demonstrated
that a number of delegates changed their minds regarding
their attitudes towards screening, many also changing
their opinion on the benefits of population screening.
From changes in questionnaire responses we can see that
by the end of the event:
 Fewer delegates said they would like to know if they
had a problem with their memory
 Fewer delegates said they would like to know they
had greater risk of dementia
 Fewer delegates said they would like to know if they
had a problem with dementia
 Fewer delegates said people should be tested for
dementia
 Fewer delegates said they thought screening was
harmless
Thirty delegates responded to the question “How often
do you think individuals should be screened for demen-
tia?” and answers varied widely; some partners responded
that screening should be conducted on a yearly basis;
others argued that it could be once a decade or never.
Eleven people made no response to this question, four
people said they didn’t know and six people said never.
Process
There are a number of factors which impact on findings.
Firstly, by only recruiting partners from the East of England
and London regions we were unable to capture a diverse
range of attitudes from across the country, meaning any
variation at regional or national (Wales and England) level
may be missed. Secondly, as some attendees volunteered
via the ASRN, there is a potential source of bias as those
with the strongest opinions and/or experiences may have
attended the event thereby skewing the feedback.
Impacts and outcomes
Findings from this public event provide some evidence
that issues related to test accuracy, existing care, lifestyle
and life view, organisational pressures, planning and the
role of support that were identified in our international
review are transferrable to UK health care. However, the
magnitude these factors determine an individual’s will-
ingness to be screened remains unknown due to cross-
cultural sensitivities.
Economic appraisal
As discussed the total cost of this PPI event was
£6,055.80. For this amount we were able to contextualise
findings from international research to a UK healthcare
setting and inform a sample of 50 members of the public
and carers about what a screening programme for
dementia might involve; its benefits and drawbacks.
While there were a number of positive outcomes from
the event, there are also a number of difficulties that
may impact on the ability to undertake PPI events in the
future. The main issues include the use of resources, in
particular staff time and costs. Timing was also an issue;
it is important to ensure that both location and date is
suitable for members of the general public. Recruitment
was also a lengthy process as we were unsure how repre-
sentative the group would be, which groups were
required and how many delegates there needed to be. In
the future researchers and funders need to make appro-
priate allowance for the considerable costs of PPI; larger
budgets for supportive care costs may be allocated in
order to improve the response rate from people with
dementia themselves. There also needs to be better
information about the availability of re-imbursement for
costs of alternative care provision.
Discussion
The main findings of this PPI exercise suggest the accept-
ability of screening is dependent upon a variety of factors
including personal beliefs, experiences and attitudes to
health. The most frequent themes that emerged were the
awareness of the disease and its implications; the accept-
ability and validity of the test; the costs to NHS; existing
health status; financial/profit motive; and the importance
of support. While individual lifestyle factors are important,
the decision to screen is inextricably linked to the lack of
ability to change dementia prognosis. Although all involved
consider dementia a serious condition, many questioned
the need to identify it early through population screening.
There are a number of strengths to this PPI exercise, in-
cluding the use of inclusive sampling methods to increase
the representativeness of partners. The format facilitated
discussions on those issues arising from the review, and
topics were examined in depth. The inclusion of lay par-
ticipants in the analysis and the writing of this article was
also helpful because it allowed for the research team to
confirm their interpretation of the discussion.
There are however a number of weaknesses. PPI is not
research and these findings should not be seen as a
replacement for robust qualitative inquiry. The pre-post
questionnaire was not powered or designed to demon-
strate statistical significance. The small number of part-
ners attending the event also limits the generalizability
of findings. Results are therefore descriptive and while
findings are transferable to other settings further research
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would be required to understand which are most appro-
priate. The study also recruited a large proportion of part-
ners who had worked with or cared for a person with
dementia, which may contribute to a recruitment and se-
lection bias and therefore may subsequently influence the
representativeness of the findings. Problematically, there is
a lack of large-scale mixed-method studies seeking to
understand the social acceptability and implications of
dementia screening; future studies could assess attitudes
and preferences through a combination of interview and
survey. Also, pen and paper tests were the focus of this
project. Attitudes towards other means of screening for
dementia, namely genetic screening, are likely to be driven
by different factors. A systematic review specifically look-
ing at these factors is underway [12].
In comparison with findings from our review of inter-
national research, there were greater concerns around the
economic incentives around screening, the provision of
social support, and the economic or social impacts of
screening programmes. This may reflect cultural differ-
ences between the British population and other countries
such as the USA which have adopted differing models of
healthcare provision.
Conclusions
Screening asymptomatic individuals for dementia raises
complex issues and a number of factors impact on its ac-
ceptability. For a few delegates, screening was seen as a
potentially positive experience; however, for others the re-
verse was true. In this event the general public had a
largely sceptical view of the benefit and validity of popula-
tion screening for dementia. Psychological and physical
health of patients, taboos about dementia, a number of
practical issues and, crucially, the perceived lack of benefit
need to be addressed before screening would be accept-
able to the population. Findings also demonstrate a level
of uncertainty about what dementia is, how it develops,
methods of identification, the prognosis and treatment of
the syndrome. It is unclear which interventions are re-
quired to change the perspectives of the general public.
Future studies can utilise the information contained in this
investigation of public opinion to inform a larger qualita-
tive research project that may answer these questions.
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